BeyondSpring, Inc. (NASDAQ:BYSI)
| Market Cap | 46.05M-35.6% |
| Revenue (ttm) | 0+100.0% |
| Net Income | -6.68M-461.8% |
| EPS | -0.17-95.4% |
| Shares Out | 41.12M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,485,548 |
| Open | 0.80 |
| Previous Close | 0.78 |
| Day's Range | 0.77 - 1.13 |
| 52-Week Range | 0.57 - 2.44 |
| Beta | 0.42 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Nov 12, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About BYSI
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$BYSI stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in BYSI holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BYSI's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BYSI Estimated quarterly lobbying spending
Source: U.S. Senate LDA
BYSI Revenue by Segment or Geography
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New BYSI patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BYSI from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in BYSI
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $218.47K |
| VXFVanguard Extended Market ETF | $212.90K |
| IWCiShares Micro-Cap ETF | $75.57K |
Estimated from each fund’s disclosed top holdings × AUM
BYSI Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from BYSI’s recent data — informational, not investment advice